Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — April 2018

Planlagt Fastgjort Låst Flyttet Genmab
1.4k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #1303

    Tak for info.

    1 Reply Last reply
    0
    • M Offline
      M Offline
      Mcjean
      wrote on sidst redigeret af
      #1304

      Altså lidt som car-t eller? toksisk, høj kompleksitet på alle parametre og fandens dyrt.

      1 Reply Last reply
      0
      • M Offline
        M Offline
        Mcjean
        wrote on sidst redigeret af
        #1305

        Nu er $ jo steget 2.5% så jeg forventer opjusteringer på stribe af diverse analytikere, de var jo gode til at nedjustere da $ faldt. Men det er nok ønsketænkning at tro det.

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JDam
          wrote on sidst redigeret af
          #1306

          Nej, ikke så potentielt toksisk og dyrt som car-t, men det er typisk noget som hospitaler selv skal 'samle': men køber isotopen og en særlig modificeret dara. Det er som sådan heller ikke et nyt koncept som car-t. Det er meget myndigheder
          , der har åbnet for muligheden, men der er stærkt overvåget.

          1 Reply Last reply
          0
          • G Offline
            G Offline
            GeorgeBest
            wrote on sidst redigeret af
            #1307

            Tak JDam

            1 Reply Last reply
            0
            • J Offline
              J Offline
              JDam
              wrote on sidst redigeret af
              #1308

              Selv tak, GeorgeBest. Nu skal man jo aldrig sige aldrig - jeg ser ikke brug af actinium komme ret højt op i linjerne til denne behandling. De andre kan ikke undværes. Actinium og andre alpha emittere har også god effekt i andre sygdomme og der er det også svært fx. PCa.

              1 Reply Last reply
              0
              • Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktørH Offline
                Helge_LarsenPI-redaktør
                wrote on sidst redigeret af
                #1309

                Tallet for Symphony Health Solution er 108,7 mio US dollars. En stigning fra februar (90,2) på 20,5 %.

                1 Reply Last reply
                0
                • Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktørH Offline
                  Helge_LarsenPI-redaktør
                  wrote on sidst redigeret af
                  #1310

                  God morgen. 🙂

                  1 Reply Last reply
                  0
                  • K Offline
                    K Offline
                    KWC
                    wrote on sidst redigeret af
                    #1311

                    Morgen. Og tak 🙂

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #1312

                      thanks Helge; that means a difference with real Q1 figures of almost 10% now

                      1 Reply Last reply
                      0
                      • BulderB Offline
                        BulderB Offline
                        Bulder
                        wrote on sidst redigeret af
                        #1313

                        Tak Helge

                        1 Reply Last reply
                        0
                        • B Offline
                          B Offline
                          bibob
                          wrote on sidst redigeret af
                          #1314

                          God morgen fra solrige Torremolinos. :-). Og tak for tallene Helge. De ser solide ud. Måske derfor det pæne luk i går. 😉

                          1 Reply Last reply
                          0
                          • M Offline
                            M Offline
                            Mcjean
                            wrote on sidst redigeret af
                            #1315

                            Tak for input JDam!

                            1 Reply Last reply
                            0
                            • M Offline
                              M Offline
                              Mcjean
                              wrote on sidst redigeret af
                              #1316

                              Nu sagde JDW jo også (engang i feb. tror jeg) at det så ud som om de havde løst flaskehalsproblematikken i US, hvolket jo burde udløse nogle andre salgstal.

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #1317

                                Tisotumab Vedotin mention in the Seattle Genetics Q1 2018 Results http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-newsArticle&ID=2345077

                                1 Reply Last reply
                                0
                                • Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktørH Offline
                                  Helge_LarsenPI-redaktør
                                  wrote on sidst redigeret af
                                  #1318

                                  " Tisotumab Vedotin (TV) Program Activities

                                  Planned Pivotal Trial Initiation: Seattle Genetics and Genmab plan to advance TV into a pivotal phase 2 trial for recurrent or metastatic cervical cancer that relapses or progresses after standard of care treatment for cervical cancer. The single-arm trial is designed to enroll approximately 100 women and could potentially support registration under the FDA’s accelerated approval regulations.

                                  1 Reply Last reply
                                  0
                                  • Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktørH Offline
                                    Helge_LarsenPI-redaktør
                                    wrote on sidst redigeret af
                                    #1319

                                    The trial is expected to begin in the first half of 2018".

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #1320

                                      "Expanding Clinical Development Program: Seattle Genetics and Genmab plan to initiate in 2018 a phase 2 trial of TV as part of a combination regimen in women with first-line metastatic cervical cancer. In addition, a phase 2 trial is expected to begin in 2018 to evaluate TV monotherapy in a range of other solid tumors"
                                      .

                                      1 Reply Last reply
                                      0
                                      • Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktør
                                        wrote on sidst redigeret af
                                        #1321

                                        Thanks E L

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #1322

                                          also the Earnings Call Transcript for those interested - https://seekingalpha.com/article/4166737-seattle-genetics-sgen-q1-2018-results-earnings-call-transcript?part=single - doesnt say much more, except that they work closely with Genmab, have visited them and that they think they will accrue the trials very rapidly and then get data 'very fast'.

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger